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Abstract
The main objective of this study was to identify single proteins or protein networks that might
be used as diagnostic biomarkers or for therapeutic purposes by evaluating the protein
expression profiling of plasma and lungs at different stages of metastatic development in a
human triple negative MDA-MB-231 breast cancer xenograft model. MDA-MB-231 tumour
cells were injected into the mammary fat pads on one side of the groin area. The mice were
sacrificed day 19 (pre-metastases) and day 54 (metastases). Non-injected mice served as
controls. Plasma was collected and lungs harvested for both immunohistochemistry and
protein analysis. The most striking observation in plasma was the initial reduction in hapto-
globin level at the pre-metastatic stage, to a following significant increase in haptoglobin
level at the metastatic stage, with a more than 4000-fold increase from the pre-metastatic to
the metastatic phase. A corresponding increase in haptoglobin level was also found in lung
tissue after metastasis. Fibrinogen beta chain also had a similar change in expression level
in plasma as haptoglobin, however not as prominent. There were also changes in plasma
thrombospondin-4 and transferrin receptor protein 1 levels, from an increase at the pre-met-
astatic stage, to a significant fall when metastases were established. This suggests that
especially changes in haptoglobin, but also fibrinogen beta chain, thrombospondin-4 and
transferrin receptor protein 1 is indicative of metastasis, at least in this breast cancer model,
and should be further evaluated as general breast cancer biomarkers.
Introduction
Breast cancer is the most common cancer among females worldwide. Each year, approximately
1.8 million patients are diagnosed with breast cancer, and more than 500 000 die from the dis-
ease [1]. Metastatic spread of breast cancer is responsible for 90% of breast cancer-related
deaths and thus remains the most important negative prognostic predictor [1]. Therefore, rec-
ognition and understanding of the metastatic process is very important.
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Metastasis, also classified as stage 4 breast cancers, is a complex process, which involves
detachment of cancer cells from the primary tumour, extracellular matrix degradation, migra-
tion to, adhesion to and proliferation in the determined distant site. Research has identified
the extracellular matrix (the “soil”) to play a crucial role for both primary tumour growth and
metastasis. Recently the microenvironment was included in the “hallmarks” of cancer along-
side those that are already well-established [2]. Thus, the development of metastases is depen-
dent on the bidirectional communication between the cancer cell and the extracellular matrix
[3]. Breast cancer spreads specifically to bone, lungs, liver, axillary glands and brain via the
haematogenous route in humans. Because of this, we must assume that it may involve activa-
tion of host-specific signalling networks and cause changes in the plasma that arise after the
primary tumour has developed. Triple negative breast cancers, such as the MDA-MB-231 used
in our study, are particularly aggressive, are often associated with the BRCA1 mutation, and is
commonly observed in younger women [4]. Once a triple negative breast cancer has become
metastatic, the time from relapse of disease to death is a lot shorter than for other sub-types of
breast cancer.
Our understanding of metastasis has increased through clinical studies [5]. However, sam-
pling at late stages limits the ability to study the metastatic process over time. The aim of this
project was to use the very aggressive and spontaneously metastasising triple negative cell line
MDA-MB-231 in vivo, in an attempt to identify possible single proteins or proteome networks
that might be used as diagnostic biomarkers or for therapeutic purposes.
Material and methods
Cell line
The highly metastatic human breast carcinoma cell line MDA-MB-231 was used. This cell line
was obtained from the American type Culture Collection (Rockville, MS, USA). MDA-MB-
231 is a triple-negative (lacking estrogen receptor, progesterone receptor and HER2 amplifica-
tion) molecular subtype of breast cancer that was derived from pleural effusion of a breast can-
cer patient suffering from widespread metastasis years after removal of her primary tumour
[6].
Culturing cells
The MDA-MB-231 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Bio-
Whittaker, Verviers, Belgium) supplemented with 100 ml/L of foetal calf serum, 100 U/ml of
penicillin and 100 μg/ml of streptomycin, 2% L-glutamine (Sigma-Aldrich, Steinheim, Ger-
many). The cells were seeded into 75 cm2 plastic tissue culture flasks (NUNC, Roskilde, Den-
mark) and cultured as a monolayer in a humidified incubator set at 37˚ C with 5% CO2 and
95% air, until approximately 80% confluence.
Animal model
A total of fifteen female NOD/SCID mice, weighing approximately 22-24g, were used in this
study. The mice were all littermates and age matched. The animals were housed under diurnal
light conditions and had free access to food and water ad libitum. The animal experiments
were approved according to The Norwegian Food Safety Authority (Project number:
20157368). The Norwegian Food Safety Authority is the competent body responsible for
authorising research projects involving animals in Norway. This is in accordance with the EU
directive 2010/63, article 36. The staff members employed by The Norwegian Food Safety
Authority are responsible veterinarians and biologist with special expertise regarding the use
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of research animals. University of Bergen has an Animal Welfare Body (equivalent to the
IACUC) with special responsibility to provide advice on matters related to the welfare of ani-
mals, advise the staff on the application of the requirement of replacement, reduction and
refinement, establish and review internal operational processes as regards monitoring, report-
ing and follow-up in relation to the welfare of animals and follow the development and out-
come of projects, taking into account the effect on the animals used. The Animal Welfare
Body review all protocols submitted for authorisation before they are sent to The Norwegian
Food Safety Authority.
Establishing primary tumours and metastasis
Cells were trypsinised and spun down for 4 min at 900 rpm, and further re-suspended in PBS.
A total of 5 × 105 MDA-MB-231 tumour cells in 0.15 mL PBS were injected orthotopically into
the mammary fat pads on one side of the groin area. All animals were anesthetised using iso-
flurane (Rhone-Poulenc Chemicals, France) in combination with N2O and O2 during experi-
ments. The animals were sacrificed during anaesthesia by cervical translocation. The
experiments were either terminated on day 19 (pre-metastasis) or on day 54 (metastasis) post
injection. Mice without tumours (non-injected) served as controls (n = 5 in each group).
Blood samples
Blood was collected in sterilised Eppendorf tubes by heart puncture during deep terminal
anaesthesia. Approximately 0.5–1 ml of blood was centrifuged at 3000 rpm for 8 min and
plasma from each separate mouse was collected and stored at -80˚C until analysed.
Tissue preparation
After sacrifice, a suture was made on one bronchus. The other lung was fixed, using approxi-
mately 1 mL of Bouin’s solution (Gurr BDH Chemicals Ltd., Poole, UK) injected into the tra-
chea. The lungs were then immediately dissected out. One lung was further fixed in new
Bouin’s solution, washed in 70% ethanol, dehydrated and embedded in paraffin using standard
procedures. Sections were stained with H & E staining and examined by light microscopy.
From the other lung, 25 mg tissue was snap frozen and prepared for protein analysis.
In order to verify the presence of metastasis, 5 random lung sections from each animal were
examined by microscopy (Nikon Digital Sight, Nikon Corporation).
Protein analysis
Sample preparation for proteomics. Lung tissue samples (approximately 25 mg) were
solubilised in 4% SDS / 0.1 M Tris-HCL with a blender before heating at 95˚C for 5 min.
Mouse plasma proteins were denatured in 4% SDS / 0.1 M Tris-HCL and heated at 95˚C for 5
min. Samples were sonicated 5 cycles at 30% amplitude for 30 sec to shear nucleic acids. The
cell debris was removed by centrifugation at 16000x g for 10 min. Protein concentrations in
the lung and plasma supernatants were measured with the Pierce BCA Protein Assay Kit
(Thermo Scientific). Further processing of each protein sample (30 μg) for LC-MS was done
according to the filter-aided sample preparation (FASP) procedure [7], as recently described
step by step elsewhere [8].
NanoLC mass spectrometry of tryptic peptides. Lyophilised Tryptic peptides (Centrivap
with a Cold trap, Labconco, MO) were reconstituted in 1% aqueous formic acid (FA) / 2% ace-
tonitrile (ACN), and 1 μg of each sample was automatically injected into an Ultimate 3000
RSLC system (Thermo Scientific, Sunnyvale, CA) connected online to a Q-Excative HF mass
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spectrometer (Thermo Scientific, Bremen, Germany). Peptides were pre-concentrated on a
pre-column (Acclaim PepMap 100, 2cm x 75μm i.d. nanoViper column, packed with 3μm C18
beads), before separation of peptides on a 50 cm analytical column (Acclaim PepMap100
nanoViper column, 75 μm i.d. × 50 cm, packed with 3 μm C18 beads) at a flow rate of 250 nl/
min. The peptides were separated utilising a biphasic gradient with 0.1% FA (solvent A) and
100% ACN (solvent B) for 120 min (5% B during trapping for 5 min followed by 5–7% B over
0.5 min, 7–22% B over 59.5 min, 22–35% B over 22 min, 35–90% over 5 min and then hold at
90% B for 10 min, then sloped to 5% B over 3 min and hold at 5% B for 15 min).
Q-excative HF. The mass spectrometer was operated in data-dependent-acquisition
mode (DDA) to automatically switch between full scan MS and MS/MS acquisition. The scan
range was 375–1500 m/z with resolution R = 120,000, and the automatic gain control (AGC)
target was set to 3e6 with a maximum injection time (IT) of 100 ms. The MS/MS acquisition
for the top 12 most intense peptides with intensity threshold >5e4, charge states 2 or more,
were isolated to a target AGC value of 1e5 with IT 110 ms and resolution R = 60,000. The isola-
tion window was 1.6 m/z, the isolation offset 1.3 m/z and the dynamic exclusion lasted for 20
seconds.
Label-free protein quantification and data analysis. The MaxQuant module (version
1.5.2.2) with the integrated MS1 peak intensity-based MaxLFQ software and Andromeda
search engine were used for identification and label-free protein quantification of LC-MS data
[9]. The raw MS data were searched against SwissProt Mus musculus database version 2016 01
(16747 entries)) with MaxQuant´s settings for label-free protein quantification as described
previously [10, 11].
Briefly, Cysteine carbamidomethylation was set as fixed modification and protein N-termi-
nal acetylation and oxidation of methionine as variable modifications. Two missed cleavages
were allowed for digestion with trypsin. The label-free quantification (LFQ) mode [11] was
selected with a minimal ratio set to two, and match-between-runs option permitted. Minimal
peptide length was seven and the false discovery rate (FDR) was 0.01 for both peptides and
proteins.
The proteomics raw files and data were uploaded to ProteomeXchange Consortium via
PRIDE partner repository [12] with the dataset identifier PXD010248 and PXD010249.
Western blot
Western blot was carried out on plasma samples directly. Protein concentration was measured
using the Pierce BCA Protein Assay Kit (Life Technologies, Thermo Fisher Scientific, Wal-
tham, MA, USA) according to the manufacturer’s specifications. Proteins were separated
using one-dimensional SDS-PAGE. Protein samples were allowed to thaw on ice and further
mixed with XT Sample Buffer, 4X (Bio-Rad Laboratories Inc, Hercules, CA, USA) in a 3:1
ratio. The proteins were denatured by boiling for 5 min at 90˚C before loading onto a 12% Pre-
cise Protein Gel (Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA) along with
a SeeBlue Plus2 Prestained Standard (Invitrogen, Carlsbad, CA, USA) and an E-PAGE Magic-
Mark Unstained Protein Standard (Life Technologies, Thermo Fisher Scientific, Waltham,
MA, USA) marker as a reference for detecting proteins of interest. Electrophoresis was run for
10 min at 95 V to stack the proteins before running for 1 h at 110 V for separation. An Invitro-
gen iBlot Dry Blotting System (Life Technologies, Thermo Fisher Scientific, Waltham, MA,
USA) was used to transfer the proteins from the gel onto a PDVF membrane. Ponceau S stain-
ing was used to determine equal loading of total protein (Sigma Aldrich, St. Louis, MO, USA),
and washed with TBS-T until Ponceau S staining was removed. Membranes were incubated in
I-Block (Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA) for 1–2 h to
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saturate the membrane and prevent unspecific binding. The membrane was subsequently
washed in TBS-T 3 x 10 min and incubated with the primary antibody at 4˚C. On the following
day, the membrane was washed in TBS-T and incubated with secondary antibody for 1.5 h at
room temperature. After the final TBS-T wash, protein-bound antibodies were detected using
the Pierce ECL Western Blotting Substrate (Life Technologies, Thermo Fisher Scientific, Wal-
tham, MA, USA) and the Bio Rad Gel Doc XR (Bio-Rad Laboratories Inc, Hercules, CA,
USA).
Antibodies
Haptoglobin, ab231000, 1:1000, Abcam, Cambridge, UK. Goat polyclonal secondary antibody
to Rabbit IgG (HRP) ab97051, 1:5000, Abcam, Cambridge, UK.
Statistical and protein analysis tools
Analysis of significant protein fold changes were performed with paired t-tests and Z-statistics
in Microsoft Excel [13]. Only proteins with p-value� 0.05 for both Z- and t-tests were consid-
ered significant. Determination of significant enriched GO terms and associated proteins were
done with the browser-based A Go Tool [14]. Proteins with significant fold changes (“fore-
ground”) were compared against all identified and quantified proteins as background with
keywords association set to GO Biological Process. The web-based STRING software (version
11.0) was used for detection of protein networks [15]. The Perseus (version 1.6.0.7) software
was used for statistical multiple sample tests; MaxQuant raw data files were filtered, and
reverse hits, potential contaminants and protein only identified by site were removed from the
matrix. The data was log2-transformed and grouped into control, pre-metastasis and metasta-
sis. Only proteins with at least 50% valid LFQ values in each group were used for statistical
analysis. The multiple sample tests were set to Anova, S0 = 0, and with permutation based
FDR used for truncation. FDR was set to 0.05, the number of randomisation to 250 and the q-
values (adjusted p-values) were reported (equivalent to the corresponding FDR threshold).
Quantified plasma and lung proteins (unique peptides�2) with both ANOVA p-values and
FDR cutoff below 0.05 are marked (ANOVA significant) in S1 Table. Boxplot was created with
SPSS (Statistic Package for the Social Science) statistic software (IBM SPSS Statistic for Wid-
ows, Version 25.0. Armonk, NY: IBM corp.).
Results
In this study we investigated the proteomic profiles of lungs and plasma at different stages of
breast cancer development in mice with MDA-MB-231 xenografts. The establishment of
metastasis was confirmed histologically. Five plasma and 5 lung samples from each group
(control, pre-metastatic and metastatic) were subjected to identical protein extraction and
LC-MC and MS/MS procedures, however one control and two pre-metastatic plasma samples
had to be discarded due to haemolysis of red blood cells (erythrocytes). We identified 389 pro-
teins for the plasma proteome, of these 339 proteins had valid label-free quantification values
after removal of potential contaminants and reverse hits.
Only proteins with p-value� 0.05 for both Z- and t-tests were considered valid. Haptoglo-
bin was the protein demonstrating greatest change by proteomics between groups and thus
the most interesting. This was confirmed by western blot (see below).
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Metastases
Histological sections showed that none of the animals had developed lung metastases at day
19, however all animals had developed metastases at day 54 (Fig 1).
Proteins in plasma
We identified 3013 proteins for the lung tissue proteome. Of these 2925 proteins had valid
label-free quantification values after removal of potential contaminants and reverse hits.
There were eight down-regulated and five up-regulated proteins in the pre-metastatic stage
(pre-metastasis vs control) as shown in Fig 2, indicating changes in protein levels in plasma
during early tumour progression. The eight significantly down-regulated proteins (FC(Log2))
> 1 and p-value� 0.05 for Z- and t-tests) are correlated to oxygen stress, specifically by down-
regulation of antioxidants (peroxiredoxin-2, superoxide dismutase) and reduced oxygen trans-
port (haptoglobin, haemoglobin subunit alpha and beta), while the 5 up-regulated proteins (p-
value� 0.05 for Z- and t-tests) display a variety of functions.
There were six down-regulated proteins in the metastatic stage versus control plasma
(metastasis vs control) and eight down-regulated proteins when the metastatic stage is com-
pared to the pre-metastatic stage (metastasis vs pre-metastasis), as shown in Fig 3 and Fig 4
respectively. Five of these are identical in the two groups and have been identified to be
involved in biological processes such as protein transport (corticosteroid-binding globulin,
collagen type I alpha 1 chain, transthyretin, adiponectin, retinol binding protein 4) and hor-
mone regulation (transthyretin, adiponectin, retinol-binding protein 4). Furthermore, 11 up-
regulated proteins in the metastatic stage versus control plasma and eight proteins were up-
regulated when comparing the metastatic to pre-metastatic stage, as shown in Fig 3 and Fig 4
respectively. Five of these are identical and they are all biologically connected to stress response
(haptoglobin, alpha-1-acid glycoprotein 2, fibrinogen gamma chain, fibrinogen beta chain,
serum amyloid A1).
Fig 1. Lung morphology. 5 x105 cells were injected in the mammary fat pad in the groin area. No metastases to the lungs were present after 19 days, however all animals
had developed metastases by day 54. Scale bar: 100 μm.
https://doi.org/10.1371/journal.pone.0215909.g001
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Fig 2. Protein fold changes (FC(Log2)) in plasma pre-metastasis (day 19) versus controls with p-value� 0.05 for Z- and
t-tests.
https://doi.org/10.1371/journal.pone.0215909.g002
Fig 3. Protein fold changes (FC(Log2)�1 or�-1) in plasma, metastasis (day 54) versus controls with p-
value� 0.05 for Z- and t-tests.
https://doi.org/10.1371/journal.pone.0215909.g003
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Metastasis signature in lung tissue
71 proteins levels were significantly changed in lung tissue before metastasis had occurred
(pre-metastasis vs control) (S2 Table). After metastases had been established in the lungs
(metastasis vs pre-metastasis) we found that 288 proteins were enriched in lung tissue (S2
Table). The two most interesting proteins identified in lung tissue after metastasis were the
ones that were also identifiable in plasma after metastasis; haptoglobin (FC(log2) 2.9) and
fibrinogen beta chain (FC(log2) 1.4). To determine whether there is evidence for a true differ-
ence in expression between the different groups, a multiple sample test was conducted (S1
Table). An SPSS box plot to show the distribution of the LFQ intensity data for haptoglobin
and fibrinogen beta chain are shown in Fig 5 for both lung tissue and plasma samples, as well
as thrombospondin-4 and transferrin receptor protein for plasma.
Using the GO tool we found only one significant GO term with higher abundance in the
pre-metastatic phase compared to the control group in lung tissue; mRNA-splicing via spliceo-
somes. More than thirty biological processes were identified as being up-regulated in lung tis-
sue after metastasis compared to the pre-metastatic phase (S3 Table). A strict selection was
made where the cut off was set at minimum 5 proteins in each enriched term, and p<0.05.
After the selection, the remaining enriched terms were identified as being involved in pro-
cesses such as cell adhesion, immune responses, positive regulation of superoxide anion gener-
ation and angiogenesis (S4 Table). Eleven enriched terms were identified as being higher in
the pre-metastatic stage compared to after metastasis had occurred, when the same strict crite-
ria as applied above there were nine remaining enriched terms. Those of interest in this study
were the following; sarcomere organisation, positive regulation of peptidyl-tyrosine phosphor-
ylation, response to hypoxia, protein localisation to plasma membrane, oxidation-reduction
process and response to drug (S4 Table). Furthermore, string analysis showed three
Fig 4. Protein fold changes (FC(Log2)�1 or�-1) in plasma, metastasis (day 54) versus pre-metastasis (day 19) with p-
value� 0.05 for Z- and t-tests.
https://doi.org/10.1371/journal.pone.0215909.g004
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dominating clusters when comparing metastasis to the pre-metastatic group (Fig 6). One clus-
ter predominantly represented proteins involved with immune responses, cell-cell interaction,
haemostasis and haematopoiesis (blue cluster). The second cluster (green cluster) involved
immune response, DNA damage, EGF receptor and haematopoiesis, and the third (red cluster)
involved metabolism, cell movement and immune responses.
Fig 5. SPSS box plot to show the distribution (median, first quartile, third quartile, minimum and maximum value) of the LFQ intensity data for four potential
biomarkers for metastatic breast cancer, including haptoglobin, fibrinogen beta chain, thrombospondin-4, and transferrin receptor protein.
https://doi.org/10.1371/journal.pone.0215909.g005
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Western blot
Western blot of the plasma samples showed a marked upregulation of haptoglobin in the post-
metastatic state, confirming the proteomics results (Fig 7). Due to the dramatic increase of
haptoglobin, with a more than 4000-fold up-regulation from pre-metastasis to the metastatic
phase, imaging was not sensitive enough to enable visualisation of the bands in the control
samples, because the metastatic samples were too dominant.
Fig 6. String analysis showed three dominating clusters when comparing metastasis (day 54) to the pre-metastatic
group (day 19) in lung tissue. The blue cluster predominantly represented proteins involved with processes in
inflammation, immune response, cell-cell interaction, haemostasis and haematopoiesis. The green cluster involved
immune response, DNA damage, EGF receptor and haematopoiesis, and the red cluster involved metabolism,
organisation of the cytoskeleton, cell movement and immune response.
https://doi.org/10.1371/journal.pone.0215909.g006
Fig 7. Western blot of plasma confirms a major up-regulation of haptoglobin after metastasis. Ponceau S was used as a loading control for total protein.
https://doi.org/10.1371/journal.pone.0215909.g007
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Discussion
The present study identified a number of proteins and biological processes that showed altered
levels in plasma and in lung tissue, both before and after spontaneous metastasis developed
from primary breast cancer (MDA-MB-231) in the mammary fat pad in mice.
The most striking observation in plasma is that haptoglobin and fibrinogen beta chain
seem to undergo a change in regulation at some point between the pre-metastatic phase (pre-
metastatic vs control) and the metastatic phase (metastatic vs pre-metastatic), and this is par-
ticularly prominent for haptoglobin. Haptoglobin changes from a 3.25-fold (FC (Log2))
down-regulation at pre-metastasis, to a dramatic 12-fold (FC (Log2)) increase after metastasis,
which is an actual 4096x upregulation. Haptoglobin binds free Hb released from erythrocytes
and inhibits oxidative activity [16]. The initial drop in haptoglobin at the pre-metastatic phase
could indicate haemolytic anaemia and most probably also be due to oxidative stress handling.
In addition to acting as an antioxidant, other functions have been associated with an increase
in haptoglobin levels. Haptoglobin has, for example, been found to be up-regulated in angio-
genesis, it is an acute phase protein in inflammation, and an increase has also been observed in
conjunction with transplants as a way of increasing inflammation in order to reject the new
graft [17]. This situation could be related to the metastatic picture, as this also involves angio-
genesis as well as an inflammatory response attempting to fight the metastatic spread. The
great increase in haptoglobin after metastasis suggests that it could potentially serve as a bio-
marker for metastasis at least in our model. This corresponds to a case-control study investi-
gating if it was possible to detect early stages of breast cancer by a serum panel of ten potential
breast cancer markers, where haptoglobin was one of them [18]. Serum had been collected
from healthy individuals, and was analysed at a later stage if they developed breast cancer.
They were not able to detect any significant difference in the selected markers, however, they
state that this could be due to the fact that blood samples were taken up to three years prior to
the patient being diagnosed with breast cancer, and that it was therefore too early for detection
of differences in levels of these proteins. They also stated that they did not know the sub-
groups of breast cancer the patients had, which could affect the outcome. A different study
looking at the expression of haptoglobin in patients with triple negative breast cancer identi-
fied it to be a potential biomarker [19]. These workers identified a correlation between expres-
sion levels of haptoglobin and patient outcome, where the patients with the highest levels had a
poorer prognosis. They therefore suggested haptoglobin to be both a prognostic marker, as
well as a potential therapeutic target. Since this is in line with our results, it is thus tempting to
suggest that haptoglobin is a possible specific biomarker for triple negative breast cancer. Hap-
toglobin has also been indicated as a serum biomarker for ovarian cancer [20, 21] and small
cell lung cancer [22]. One study has also reported that haptoglobin could participate with
STAT3 and HIF-1a in promoting angiogenesis and cell migration, and thus contributes to
driving tumour growth and invasion [23]. In addition, our results show that the upregulation
of haptoglobin is also reflected in the lungs after the establishment of metastasis, where we
identified an almost 3-fold upregulation of the protein.
In the present study fibrinogen beta chain was shown to be down-regulated around 3-fold
(FC(Log2)) in the pre-metastatic phase, however after metastasis it is up-regulated about
4-fold (FC (Log2)). Fibrinogen (alpha, beta and gamma chain) has been found to be up-regu-
lated in advanced breast cancer [24]. It also plays an important role in cancer pathophysiology,
and it is a determinant of metastatic potential as fibrinogen deficiency diminished the forma-
tion of lung metastasis in a murine melanoma and a murine lung carcinoma model. However,
it does not seem to play a role in the growth of established metastases [25]. In the present study
the initial pre-metastatic reduction, and subsequent increase after metastasis in both
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haptoglobin and fibrinogen beta chain found in the present study shows that these proteins
might be good biomarkers in the prediction of metastasis.
Thrombospondin-4 and transferrin receptor protein 1 also exhibited similar changes in
expression levels, however these were not as prominent as the changes in levels seen in hapto-
globin and fibrinogen beta chain. Thrombospondin-4 and transferrin receptor protein 1 had
an approximate fold change (FC(log2)) upregulation of 0.5 and 0.6 respectively before the
establishment of metastasis (B vs A). After metastasis thrombospondin-4 had a down-regu-
lated fold change of approximately -2 (FC (Log4)), whilst transferrin receptor protein 1 had a
fold change (FC (Log2)) of -2.5. Thrombospondin 4 is up-regulated at the pre-metastatic stage.
It is an adhesive glycoprotein and is said to be activated during tissue remodelling processes
such as wound healing and cancer [26]. Thrombospondin 4 contributes to the activation of
stromal responses exhibited during tumour progression and this may facilitate invasion of
tumour cells in breast cancer [27]. The up-regulation of this protein is therefore indicative of
enhanced cellular migration and proliferation, and thus a possible biomarker for metastatic
potential.
The eight down-regulated proteins in the pre-metastasis stage (pre-metastatic vs control)
are correlated to oxygen stress, while the 5 up-regulated ones have varying functions. Two
anti-oxidant enzymes were significantly down-regulated. The superoxide dismutase and per-
oxiredoxin-2 are both antioxidants, and thus reduces the damage induced by free radicals in
the body. Hence, a reduced anti-oxidant level is indicative of enhanced free radical levels in
this first step towards metastasis. Furthermore, there is downregulation of haemoglobin (both
subunits), which is a protein that is involved in O2 transport, and an up-regulation of transfer-
rin receptor protein, which is a protein responsible for iron transport into cells. Both of these
indicate anaemia/reduced O2 transport levels prior to the development of metastases. An
increase in transferrin receptor protein more specifically indicates iron-deficiency anaemia
[28]. Anaemia is known to be associated with poor outcome in patients with breast cancer [29,
30]. Apolipoprotein M, which is also up-regulated, is involved in lipid transport but its biologi-
cal function remains to be elucidated [31]. Apolipoprotein M mRNA has however been closely
associated with nodal metastasis in colon cancer [32].
No changes in biological processes of interest were observed in the lung tissue before metas-
tases were established when comparing these to the controls (pre-metastatic vs control). How-
ever, after the development of metastases many biological processes were altered (metastatic vs
pre-metastatic). At the pre-metastatic stage processes involved in drug response, oxidation-
reduction processes, response to hypoxia and protein localisation to plasma membrane were
more active than after development of metastases, and are therefore of interest. Hypoxia is
known to be a prognostic marker for poor patient outcome [33, 34], and previous studies from
our group have demonstrated that the use of hyperbaric oxygen treatment for the purpose of
reducing hypoxia limits tumour growth and development of metastasis [35–41]. An up-regula-
tion of hypoxic response at this point could therefore suggest this to be a crucial stage for the
development of metastasis. After the establishment of metastasis up-regulated biological pro-
cesses of interest were related to immune responses and cell-matrix adhesion where fibrinogen
beta chain contributes to both these processes, and positive regulation of angiogenesis. These
processes suggest accelerated tumour growth, establishment of metastases, and that the
tumour has ability to promote angiogenesis for the purpose of increasing supply of nutrients.
The protein we discovered to be most up-regulated after metastasis, haptoglobin, was found to
contribute to the biological process of immunity, more specifically defence against bacteria.
String analysis showed three dominating clusters when comparing the metastatic to the
pre-metastatic stage which all showed general interactions between processes involved in
immune response, cell-cell interaction, cell movement, DNA-damage, haemostasis and
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haematopoesis. These are all expected processes in tumour development and the establishment
of metastasis.
Conclusion
The procedure of collecting a blood sample from a patient is a simple procedure, and a plasma
sample is thus easily obtainable from patients. It is therefore highly favourable to be able to
identify proteins in plasma that could aid the identification of breast cancer at an early stage.
In plasma the most prominent changes in protein expression were haptoglobin and fibrinogen
beta chain, from a marked down-regulation before development of metastasis to significant
up-regulation after the establishment of metastasis, with haptoglobin being the most striking
observation. This is also reflected in lung tissue after metastasis. There were also changes in
plasma thrombospondin-4 and transferring receptor protein 1 levels, from an increase at the
pre-metastatic stage, to a significant fall when metastases were established. Taken together this
suggests that especially changes in haptoglobin levels, but also fibrinogen beta chain, throm-
bospondin-4 and transferrin receptor protein 1 levels are indicative of metastasis in at least
this breast cancer model, and should be further evaluated as general breast cancer biomarkers.
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